The scholarly research imaged sufferers with technetium-99m-labeled EthylenediCysteine-Glucosamine.

Cell>Point reviews encouraging results from Stage 2a cardiovascular clinical research of 99mTc-EC-G Cell>Stage announced today encouraging results following the conclusion of its Phase 2a cardiovascular clinical study performed by Cardiovascular Imaging Technologies of Kansas Town, Missouri. The scholarly research imaged sufferers with technetium-99m-labeled EthylenediCysteine-Glucosamine , Cell>Stage's proprietary nuclear imaging product applicant, which is target particular for detecting the existence and degree of ischemia in patients with Coronary Artery Disease cialisnorge.eu . The results from the Phase 1 and 2a studies also show that 99mTc-EC-G gets the potential to accurately diagnose myocardial ischemia in less than 30 minutes post injection in sufferers studied at rest only.

Other Posts From Category "health":

Related Posts